US5138060A
(en)
*
|
1991-01-03 |
1992-08-11 |
Pfizer Inc. |
Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
|
EP0589924B1
(de)
*
|
1991-06-20 |
1996-09-04 |
Pfizer Inc. |
Fluoralkoxybenzylaminoderivate stickstoffhaltiger heterocyclen
|
JP2656702B2
(ja)
*
|
1992-03-23 |
1997-09-24 |
ファイザー製薬株式会社 |
ペプチド性キヌクリジン
|
US5721255A
(en)
*
|
1992-08-19 |
1998-02-24 |
Pfizer Inc. |
Substituted benzylamino nitrogen containing non-aromatic heterocycles
|
JP2656699B2
(ja)
*
|
1992-10-21 |
1997-09-24 |
ファイザー製薬株式会社 |
置換ベンジルアミノキヌクリジン
|
JP2656700B2
(ja)
*
|
1992-10-28 |
1997-09-24 |
ファイザー製薬株式会社 |
置換キヌクリジン誘導体
|
US5837711A
(en)
*
|
1992-10-28 |
1998-11-17 |
Pfizer Inc. |
Substituted quinuclidines as substance P antagonists
|
DE69328975T2
(de)
*
|
1992-12-10 |
2000-11-09 |
Pfizer |
Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
|
IL109646A0
(en)
*
|
1993-05-19 |
1994-08-26 |
Pfizer |
Heteroatom substituted alkyl benzylamino-quinuclidines
|
JP2822274B2
(ja)
*
|
1993-05-19 |
1998-11-11 |
ファイザー製薬株式会社 |
P物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
|
US5393762A
(en)
*
|
1993-06-04 |
1995-02-28 |
Pfizer Inc. |
Pharmaceutical agents for treatment of emesis
|
ATE171945T1
(de)
*
|
1993-07-15 |
1998-10-15 |
Pfizer |
Benzyloxychinuclidine als substanz p antagonisten
|
DE69433744T2
(de)
*
|
1993-09-17 |
2004-10-14 |
Pfizer Inc. |
3-amino-5-carboxy-substituierte piperidine und 3-amino-4-carboxy-substituierte pyrrolidine als tachykinin-antagonisten
|
US6083943A
(en)
*
|
1993-09-17 |
2000-07-04 |
Pfizer Inc |
Substituted azaheterocyclecarboxylic acid
|
EP0653208A3
(de)
*
|
1993-11-17 |
1995-10-11 |
Pfizer |
Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
|
EP0659409A3
(de)
*
|
1993-11-23 |
1995-08-09 |
Pfizer |
Substanz P Antagonisten zur Hemmung der Angiogenese.
|
EP0655246A1
(de)
*
|
1993-11-30 |
1995-05-31 |
Pfizer Inc. |
Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
|
FR2728169A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
|
FR2728165A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
|
FR2728166A1
(fr)
|
1994-12-19 |
1996-06-21 |
Oreal |
Composition topique contenant un antagoniste de substance p
|
PE8798A1
(es)
*
|
1995-07-17 |
1998-03-02 |
Pfizer |
Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
|
TW458774B
(en)
|
1995-10-20 |
2001-10-11 |
Pfizer |
Antiemetic pharmaceutical compositions
|
FR2741262B1
(fr)
|
1995-11-20 |
1999-03-05 |
Oreal |
Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
|
MX9706944A
(es)
*
|
1996-09-12 |
1998-08-30 |
Pfizer |
Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
|
NZ329807A
(en)
*
|
1997-04-23 |
2000-07-28 |
Pfizer |
NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
|
DE60038185T2
(de)
|
1999-11-03 |
2009-02-19 |
Amr Technology, Inc. |
Arly- und heteroaryl-substituierte tetrahydroisoquinoline und ihre verwendung als hemmer der wiederaufnahme von norepinephrin, dopamin und serotonin
|
US7163949B1
(en)
|
1999-11-03 |
2007-01-16 |
Amr Technology, Inc. |
4-phenyl substituted tetrahydroisoquinolines and use thereof
|
KR100821410B1
(ko)
|
2000-07-11 |
2008-04-10 |
에이엠알 테크놀로지, 인크. |
4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
|
DOP2002000332A
(es)
|
2001-02-14 |
2002-08-30 |
Warner Lambert Co |
Inhibidores de piridina de metaloproteinasas de la matriz
|
US6861526B2
(en)
*
|
2002-10-16 |
2005-03-01 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
|
KR101412339B1
(ko)
|
2004-07-15 |
2014-06-25 |
알바니 몰레큘라 리써치, 인크. |
아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를차단하기 위한 용도
|
US8362075B2
(en)
|
2005-05-17 |
2013-01-29 |
Merck Sharp & Dohme Corp. |
Cyclohexyl sulphones for treatment of cancer
|
NZ565111A
(en)
|
2005-07-15 |
2011-10-28 |
Amr Technology Inc |
Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
|
WO2007041052A2
(en)
|
2005-09-29 |
2007-04-12 |
Merck & Co., Inc. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
GB0603041D0
(en)
|
2006-02-15 |
2006-03-29 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
WO2008039327A2
(en)
|
2006-09-22 |
2008-04-03 |
Merck & Co., Inc. |
Method of treatment using fatty acid synthesis inhibitors
|
US20110218176A1
(en)
|
2006-11-01 |
2011-09-08 |
Barbara Brooke Jennings-Spring |
Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
|
WO2008084261A1
(en)
|
2007-01-10 |
2008-07-17 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa |
Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
|
EP2117538A1
(de)
|
2007-01-24 |
2009-11-18 |
Glaxo Group Limited |
Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
|
US8106086B2
(en)
|
2007-04-02 |
2012-01-31 |
Msd K.K. |
Indoledione derivative
|
EP2170076B1
(de)
|
2007-06-27 |
2016-05-18 |
Merck Sharp & Dohme Corp. |
4-carboxybenzylamino-derivate als histondeacetylase-hemmer
|
CA2717509A1
(en)
|
2008-03-03 |
2009-09-11 |
Tiger Pharmatech |
Tyrosine kinase inhibitors
|
US9156812B2
(en)
|
2008-06-04 |
2015-10-13 |
Bristol-Myers Squibb Company |
Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
|
UA105182C2
(ru)
|
2008-07-03 |
2014-04-25 |
Ньюрексон, Інк. |
Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
|
WO2010114780A1
(en)
|
2009-04-01 |
2010-10-07 |
Merck Sharp & Dohme Corp. |
Inhibitors of akt activity
|
CN102595902B
(zh)
|
2009-05-12 |
2015-04-29 |
阿尔巴尼分子研究公司 |
7-([1,2,4]***并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
|
ES2446971T3
(es)
|
2009-05-12 |
2014-03-11 |
Albany Molecular Research, Inc. |
Tetrahidroisoquinolinas sustituidas con arilo, heteroarilo, y heterociclo y su uso
|
WO2010132487A1
(en)
|
2009-05-12 |
2010-11-18 |
Bristol-Myers Squibb Company |
CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
|
NZ599343A
(en)
|
2009-10-14 |
2014-05-30 |
Merck Sharp & Dohme |
Substituted piperidines that increase p53 activity and the uses thereof
|
WO2011163330A1
(en)
|
2010-06-24 |
2011-12-29 |
Merck Sharp & Dohme Corp. |
Novel heterocyclic compounds as erk inhibitors
|
US8518907B2
(en)
|
2010-08-02 |
2013-08-27 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
|
RU2624045C2
(ru)
|
2010-08-17 |
2017-06-30 |
Сирна Терапьютикс,Инк |
ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
|
EP2608669B1
(de)
|
2010-08-23 |
2016-06-22 |
Merck Sharp & Dohme Corp. |
Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer
|
WO2012030685A2
(en)
|
2010-09-01 |
2012-03-08 |
Schering Corporation |
Indazole derivatives useful as erk inhibitors
|
WO2012036997A1
(en)
|
2010-09-16 |
2012-03-22 |
Schering Corporation |
Fused pyrazole derivatives as novel erk inhibitors
|
WO2012058210A1
(en)
|
2010-10-29 |
2012-05-03 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
|
EP2654748B1
(de)
|
2010-12-21 |
2016-07-27 |
Merck Sharp & Dohme Corp. |
Indazolderivate als erk-hemmer
|
US20140045832A1
(en)
|
2011-04-21 |
2014-02-13 |
Piramal Enterprises Limited |
Insulin-Like Growth Factor-1 Receptor Inhibitors
|
WO2013063214A1
(en)
|
2011-10-27 |
2013-05-02 |
Merck Sharp & Dohme Corp. |
Novel compounds that are erk inhibitors
|
EP3358013B1
(de)
|
2012-05-02 |
2020-06-24 |
Sirna Therapeutics, Inc. |
Sina-zusammensetzungen
|
US9233979B2
(en)
|
2012-09-28 |
2016-01-12 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
PT2925888T
(pt)
|
2012-11-28 |
2017-12-13 |
Merck Sharp & Dohme |
Composições e métodos para tratamento do cancro
|
CA2895504A1
(en)
|
2012-12-20 |
2014-06-26 |
Merck Sharp & Dohme Corp. |
Substituted imidazopyridines as hdm2 inhibitors
|
WO2014120748A1
(en)
|
2013-01-30 |
2014-08-07 |
Merck Sharp & Dohme Corp. |
2,6,7,8 substituted purines as hdm2 inhibitors
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
US10947234B2
(en)
|
2017-11-08 |
2021-03-16 |
Merck Sharp & Dohme Corp. |
PRMT5 inhibitors
|
EP3833667B1
(de)
|
2018-08-07 |
2024-03-13 |
Merck Sharp & Dohme LLC |
Prmt5-inhibitoren
|
WO2020033282A1
(en)
|
2018-08-07 |
2020-02-13 |
Merck Sharp & Dohme Corp. |
Prmt5 inhibitors
|